Abstract: Azenosertib (ZN-c3) is a highly potent and selective oral WEE1 kinase inhibitor currently under clinical evaluation for the treatment of advanced and metastatic solid tumors, providing a strong therapeutic rationale for gastrointestinal and other p53-mutated cancers. By inhibiting WEE1, Azenosertib forces cancer cells with defective G1/S checkpoints to prematurely enter mitosis, leading to DNA replication stress and mitotic catastrophe. Compared to first-generation WEE1 inhibitors like adavosertib, Azenosertib demonstrates improved specificity and a more favorable safety profile, particularly regarding hematological toxicities. This review synthesizes current literature on Azenosertib, detailing its pharmacological activity, molecular mechanism of action, structure-activity relationship, current limitations, and future perspectives in oncology, including its potential in combination therapies.
1. Introduction
Over 50% of all human tumors harbor mutations in the p53 tumor suppressor gene, a critical factor in tumor development and genomic stability [1]. In healthy cells, p53 regulates the G1/S cell cycle checkpoint in response to DNA damage. However, cancer cells lacking functional p53 are defective at this checkpoint and become highly dependent on the G2/M checkpoint to repair DNA damage and maintain genomic stability [1]. WEE1 kinase is a crucial nuclear protein that oversees this G2/M checkpoint [1] [2]. By overriding the G2/M checkpoint, WEE1 inhibitors preferentially sensitize p53-defective tumor cells to DNA damage, inducing mitotic catastrophe while sparing normal cells with wild-type p53 [1].
Azenosertib (ZN-c3), developed by Zentalis Pharmaceuticals, is a novel, orally bioavailable WEE1 inhibitor [1] [2]. It was designed to overcome the limitations of earlier WEE1 inhibitors, such as adavosertib (AZD1775), which were hindered by off-target effects and severe dose-limiting toxicities [1]. Azenosertib is currently being evaluated in multiple clinical trials for advanced solid tumors, offering a promising targeted approach for malignancies characterized by p53 mutations and high replication stress, including gastrointestinal cancers [1] [2].
2. Pharmacological Activity
Azenosertib exhibits potent pharmacological activity against WEE1, with an in vitro half-maximal inhibitory concentration (IC50) of 3.9 nM [2]. Its clinical activity was recently reported in a Phase 1 dose-escalation trial involving 55 patients with advanced or metastatic solid tumors [1]. In the clinical trial NCT04158336, 39 treated subjects with advanced or metastatic tumors resistant to all current therapy models received single dose escalations ranging from 25 to 450 mg orally once daily (QD) [1].
The drug demonstrated impressive anti-tumor efficacy and was deemed safe and tolerable [1] [2]. Among the evaluated patients, five achieved stable disease and two exhibited partial responses. Notably, one partial response showed a 42% reduction in overall tumor burden, while another demonstrated a 56% reduction [1]. Based on the maximum tolerated dose (MTD) observed in these studies, the recommended Phase II dose for Azenosertib was established at 300 mg [1]. Furthermore, Azenosertib is being investigated not only as a monotherapy but also in combination regimens, such as with the PARP inhibitor Talazoparib, the PD1 inhibitor Pembrolizumab, and chemotherapeutic agents like carboplatin and pegylated liposomal doxorubicin (PLD) [1].
3. Molecular Mechanism of Action
The primary mechanism of action of Azenosertib involves the targeted inhibition of WEE1 kinase. Under physiological conditions, WEE1 regulates the timing of mitotic entry by phosphorylating the Cyclin-dependent Kinase 1 (CDK1) at the tyrosine 15 (Tyr15) residue [1] [2]. This inhibitory phosphorylation disables the CDK1/Cyclin B (mitotic-promoting factor) complex, arresting the cell cycle at the G2/M transition to allow for the repair of damaged DNA [1] [2]. WEE1 also regulates CDK2 activity during the S phase to control DNA replication [2].
By inhibiting WEE1, Azenosertib prevents the inhibitory phosphorylation of CDK1 and CDK2. In cancer cells—particularly those with p53 mutations that already lack a functional G1/S checkpoint—this inhibition forces premature entry into mitosis despite the presence of unrepaired DNA damage [1] [2]. This premature mitotic entry leads to aberrant chromosomal segregation, replication fork collapse, nucleotide shortage, and ultimately, cell death via mitotic catastrophe and apoptosis [1] [2].
4. Structure-Activity Relationship (SAR)
While extensive structural derivatives are not fully detailed in the provided literature, Azenosertib (ZN-c3) is identified with the chemical formula C2H4O6Zn and the PubChem CID 131855165 [1]. A critical aspect of its structure-activity relationship is its high selectivity for WEE1 kinase (IC50 = 3.9 nM) compared to first-generation inhibitors [2]. For instance, the earlier WEE1 inhibitor adavosertib suffered from lower specificity, notably exhibiting off-target inhibition of Polo-like kinase 1 (PLK1) [1]. The structural refinement in Azenosertib avoids secondary targets like PLK1, which directly translates to a significant reduction in blood-related side effects and improved overall tolerability in clinical settings [1] [2].
5. Current Limitations
Despite its improved safety profile over adavosertib, Azenosertib is not without limitations and adverse effects. In Phase 1 trials, side effects were mostly mild to moderate, with gastrointestinal disturbances being the most prominent. Nausea affected approximately half of the 55 patients evaluated for safety, while diarrhea, fatigue, and vomiting afflicted less than one-third of the cohort [1]. Although hematological toxicities were significantly reduced compared to older WEE1 inhibitors, they still occurred in a small subset of patients: 1.8% suffered a low white blood cell count, 7.2% had a low platelet count, and 7.2% developed anemia [1].
Additionally, therapeutic resistance remains a challenge for WEE1 inhibitors. Preclinical models indicate that cancer cells can develop resistance through several mechanisms, including the upregulation of PKMYT1 (a redundant kinase that also phosphorylates CDK1/2), overexpression of Cyclin E, loss of PTEN, and mutations in the G1/S regulatory machinery (such as SKP2, CUL1, or CDK2) [1] [2]. These resistance pathways highlight the limitation of using Azenosertib as a standalone monotherapy in certain genetic contexts.
6. Future Perspectives
The future clinical development of Azenosertib is highly focused on combination therapies and biomarker-driven patient selection. Because of its favorable safety profile, Azenosertib is particularly well-suited for use in combination regimens [1]. Ongoing clinical trials (e.g., NCT04158336, NCT04516447, NCT04814108, and NCT04972422) are evaluating its efficacy alongside PARP inhibitors (Talazoparib), immune checkpoint inhibitors (Pembrolizumab), and traditional chemotherapies (carboplatin) [1] [2]. Combining WEE1 inhibition with immunotherapy is especially promising, as overriding the G2/M checkpoint has been shown to sensitize cancer cells to cytotoxic T-lymphocyte (CTL) killing and upregulate MHC class 1 antigens and the STING pathway [1] [2].
Furthermore, identifying reliable predictive biomarkers will be crucial for the successful clinical translation of Azenosertib in solid tumors, including gastrointestinal cancers. While p53 mutation status is a primary indicator of vulnerability to WEE1 inhibition, other genetic signatures—such as CCNE1 amplification, SKP2/CUL1 overexpression, LKB1 deficiency, and SETD2 alterations—are being explored to stratify patients who are most likely to achieve a durable clinical response [1] [2].
